Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer

Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer

Na Qu,1 Robert J Lee,1,2 Yating Sun,1 Guangsheng Cai,1 Junyang Wang,1 Mengqiao Wang,1 Jiahui Lu,1 Qingfan Meng,1 Lirong Teng,1 Di Wang,1 Lesheng Teng1,3 1School of Life Sciences, Jilin University, Changchun, People’s Republic of China; 2Division of Pharmaceutics, College of Pharmacy, The...

Full description

Bibliographic Details
Main Authors:	Qu N, Lee RJ, Sun Y, Cai G, Wang J, Wang M, Lu J, Meng Q, Teng L, Wang D
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-07-01
Series:	International Journal of Nanomedicine
Subjects:	cabazitaxel human serum albumin nanoparticle drug delivery toxicity prostate cancer
Online Access:	https://www.dovepress.com/cabazitaxel-loaded-human-serum-albumin-nanoparticles-as-a-therapeutic--peer-reviewed-article-IJN

Similar Items

Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy
by: Sun Y, et al.
Published: (2018-12-01)

Folate Receptor-Targeted Albumin Nanoparticles Based on Microfluidic Technology to Deliver Cabazitaxel
by: Fanchao Meng, et al.
Published: (2019-10-01)

The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients
by: Naoki Terada, et al.
Published: (2019-02-01)

ESTIMATION OF TOXIC EFFECTS OF MEDICINAL PREPARATION OF CABAZITAXEL
by: O. I. Avdeeva, et al.
Published: (2019-01-01)

Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety
by: M. I. Volkova, et al.
Published: (2019-06-01)

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
by: Patel SA, et al.
Published: (2017-08-01)

Retreatment with cabazitaxel in a long-surviving patient with castration-resistant prostate cancer and visceral metastasis
by: Raquel Luque Caro, et al.
Published: (2018-01-01)

Critical appraisal of cabazitaxel in the management of advanced prostate cancer
by: Sumanta Kumar Pal, et al.
Published: (2010-12-01)

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
by: Donald Colbourn
Published: (2012-06-01)

Pleuropulmonary and Lymph Node Progression after Docetaxel - Benefits from Treatment with Cabazitaxel in Metastatic Prostate Cancer
by: Angel Segura Huerta, et al.
Published: (2013-07-01)

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
by: Yohei Sekino, et al.
Published: (2019-08-01)

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
by: Vanita Noronha, et al.
Published: (2016-08-01)

Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study
by: Takashi Matsumoto, et al.
Published: (2021-06-01)

Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model
by: Lisanne Mout, et al.
Published: (2018-01-01)

Combination Therapy of Metastatic Castration-Recurrent Prostate Cancer: Hyaluronic Acid Decorated, Cabazitaxel-Prodrug and Orlistat Co-Loaded Nano-System
by: Qu Z, et al.
Published: (2021-08-01)

Tumor lysis syndrome following cabazitaxel administration for metastatic castration‐resistant prostate cancer: A case report
by: Masashi Oshima, et al.
Published: (2019-07-01)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
by: Peng-Fei Zhang, et al.
Published: (2021-01-01)

Anti prostate cancer therapy: Aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles
by: Yougan Chen, et al.
Published: (2020-07-01)

Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report
by: Takeo Kosaka, et al.
Published: (2019-06-01)

Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer
by: Johann de Bono, et al.
Published: (2016-03-01)

Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer
by: Gianpaolo Perletti
Published: (2016-03-01)

The role of taxanes in prostate cancer: literature review
by: A. K. Norsov, et al.
Published: (2018-07-01)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
by: Anieta M. Sieuwerts, et al.
Published: (2019-08-01)

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
by: Nicolas Delanoy, et al.
Published: (2021-03-01)

Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study
by: Hideyasu Matsuyama, et al.
Published: (2020-07-01)

Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report
by: Yoshinori Yanai, et al.
Published: (2019-07-01)

Efficacy and safety of enzalutamide, abiraterone and cabazitaxel in post-docetaxel treatment of castration-resistant prostate cancer: meta-analysis data
by: P. V. Mazin, et al.
Published: (2018-01-01)

Evaluation of the efficacy and safety of cabazitaxel in combination with prednisone in patients with metastatic castration-resistant prostate cancer who have previously received docetaxel chemotherapy in daily clinical practice. Results of a Russian multicenter prospective study
by: B. Ya. Alekseev, et al.
Published: (2020-04-01)

CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series
by: Geethal N. Malalagama, et al.
Published: (2017-06-01)

Cabazitaxel-induced stabilization of microtubules enhances radiosensitivity in ovarian cancer cells
by: Charles eKunos, et al.
Published: (2013-09-01)

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)
by: Javier Puente, et al.
Published: (2019-08-01)

FLUORESCENCE AND THE STRUCTURES OF SERUM ALBUMINS.
by: ELSHEIKH, FATHELRAHMAN ABBAS.
Published: (1987)

Comparison of clinical-economic evaluation of cabazitaxel and abiraterone for prostate cancer based on the results of clinical trials and real world data
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer
by: Fukao, T., et al.
Published: (2022)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Spectroscopic Technique-Based Comparative Investigation on the Interaction of Theaflavins with Native and Glycated Human Serum Albumin
by: Jinhui Xu, et al.
Published: (2019-08-01)

Cabazitaxel-Loaded Nanocarriers for Cancer Therapy with Reduced Side Effects
by: Nagavendra Kommineni, et al.
Published: (2019-03-01)

A novel adjuvant : polymerised serum albumin beads
by: Dewar, John Barr
Published: (1985)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Splice variants of androgen receptor and prostate cancer
by: Orazio Caffo, et al.
Published: (2016-05-01)